New Delhi: In a big move, Bharat Biotech’s Covaxin has reportedly received approval from Subject Expert Committee (SEC) on COVID-19 for emergency use in children above 2 years in India.
The SEC has submitted recommendations to Drugs Controller General of India (DCGI) for approval of the vaccine for use on children, stated reports.
Once approved, Covaxin will become only second vaccine cleared for use on kids and the only such vaccine for toddlers too. In August, Zydus Cadilla’s three-dose DNA jab was allowed to be used on adults and children over 12.
The Hyderabad-based company had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September.
A third potential vaccine for kids is Serum Institute’s Novavax, for which the DCGI last month cleared trials for children between seven and 11 years.
Comments are closed.